Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women
Status:
COMPLETED
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This clinical trial aimed to determine whether intravenous ferric carboxymaltose is more useful than iron sucrose for treating anemia in pregnant women.
The main question it aimed to answer was:
Is intravenous ferric carboxymaltose is more useful than iron sucrose for treating iron deficiency anemia in pregnant women.
Sixty pregnant women with iron deficiency anemia were enrolled to one of two intravenous treatments.
* Participants in ferrous carboxymaltose group received a maximum dose of 1000 mg per sitting diluted in 200 ml 0.9% normal saline and administered as an IV infusion over 30 min.
* Participants in iron sucrose group were administered an infusion of 300 mg in 200 ml NS over 15-20 min twice weekly till dosage was completed, not exceeding 600 mg per week.